Insulin Degludec NDC 73070-503

Product information

Brand name (proprietary)

Insulin Degludec

Generic name (nonproprietary)

insulin degludec

Active ingredients

Insulin degludec — 200 U/mL

Dosage form

Injection, Solution

Route

Subcutaneous

Labeler

Novo Nordisk Pharma, Inc.

Product type

Prescription drug

Marketing category

BLA — Biologics License ApplicationApplication BLA 203314

Marketing start

Jul 1, 2022

Marketing end

Oct 31, 2027

Other FDA classes

Insulin (Chemical structure)

Identifiers

Product ID 73070-503_6bb8d7a1-4fd3-4c63-8a88-910bbcb3f1adSPL ID 6bb8d7a1-4fd3-4c63-8a88-910bbcb3f1adSPL set ID c1be283d-4b1d-4996-b2a7-4488dbff3037RxCUI 1670011, 1670021, 2107520UNII 54Q18076QB

Pharmacologic class

Insulin Analog

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No drug-specific HCPCS code in Med-Code's directory for this product. The directory is curated and not complete — check the current CMS HCPCS file before billing.

Administration

Drug administration (CPT 96360–96549)

When a clinician administers the drug, the administration is reported separately. Codes in this range cover hydration, therapeutic injections and infusions, and chemotherapy or other complex drug administration. The right code depends on route, duration and drug type, and self-administered drugs are not billed this way.

How CPT relates to drug billing

NDC on a medical claim

N473070050315 followed by a unit qualifier and the quantity Copy

Package 73070-0503-15. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Other NDCs under BLA 203314

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.